Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
SMFR.US
D. Connecticut
Court
On August 15, 2022, Sema4 disclosed that it had “reversed $30.1 million of revenue this quarter related to prior periods,” in connection with negotiations with “one of larger commercial payors regarding the potential recoupment of payments for Sema4 carrier screening services rendered from 2018 to early 2022.”
Furthermore, The Company also announced that it was eliminating 13% of its workforce as part of a series of restructuring and corporate realignments.
Finally, Sema4 announced changes to its leadership team, including that Schadt was stepping down from his roles as President and Chief R&D Officer.
On this news, Company’s stock plunged 33.3% on August 16, 2022, seriously damaging investors.
Taking all the disclosed facts and subsequent actions into account there is reason to suspect Sema4's leaders of misconduct, in particular in terms of information disclosure to investors.
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Negligence
Omissions
Suspected Party
Directors
Management
Service Provider
Security Type
Stocks
Trade Direction
Long
Shock Event Date
15 August 2022
Collecting participants…
Created by Stan Vick, Scout

Sema4 Holdings Corp

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, ...

    Ticker
    SMFR.US
    ISIN
    US81663L1017
    CIK
    1818331
    Sector
    Healthcare
    Industry
    Healthcare Providers & Services
    Country
    USA
    Address
    North Tower, Stamford, CT, United States, 06902